COCRYSTAL PHARMA NEW O.N. (8CC) — Financial Flexibility Index
COCRYSTAL PHARMA NEW O.N. (8CC) has a Financial Flexibility Index of -0.51x as of December 2025. Free cash flow of €-1.74 Million (operating CF €-1.74 Million minus capex €0.00) represents -1% of total liabilities (€3.38 Million). Check how tangible is COCRYSTAL PHARMA NEW O.N.'s equity to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
COCRYSTAL PHARMA NEW O.N. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for COCRYSTAL PHARMA NEW O.N. across 5 annual periods. For the full cash flow conversion analysis, see 8CC cash flow metrics.
Annual Financial Flexibility Index for COCRYSTAL PHARMA NEW O.N. (2021–2025)
Year-by-year free cash flow to debt coverage for COCRYSTAL PHARMA NEW O.N.. Explore COCRYSTAL PHARMA NEW O.N. cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.42x | €-8.18 Million | €-8.19 Million | €3.38 Million | ▲ +42.2% |
| 2024 | -4.19x | €-16.48 Million | €-16.48 Million | €3.93 Million | ▼ -40.4% |
| 2023 | -2.98x | €-14.55 Million | €-14.67 Million | €4.88 Million | ▲ +82.2% |
| 2022 | -16.78x | €-21.36 Million | €-21.43 Million | €1.27 Million | ▼ -144.1% |
| 2021 | -6.87x | €-12.67 Million | €-12.72 Million | €1.84 Million | — |